Core Viewpoint - China Resources Medical (01515.HK) expects a decline in profit attributable to shareholders for the reporting period, projecting a range of approximately RMB 467 million to RMB 516 million, which represents a decrease of about 17.5% to 8.9% compared to the profit of approximately RMB 566 million for the fiscal year ending December 31, 2024 [1] Financial Performance - The company anticipates a profit attributable to shareholders decline of approximately 43.5% to 37.6% when excluding a one-time compensation of approximately RMB 210 million related to the YanHua IOT agreement and corresponding corporate income tax [1] - The decrease in profit attributable to shareholders for the first half of 2025, after excluding the YanHua compensation, is expected to narrow by approximately 13.9 to 19.8 percentage points compared to the 57.4% decline year-on-year with the same period in 2024 [1]
华润医疗(01515.HK)2025年度净利润同比下降约8.9%至17.5%